Status:
UNKNOWN
The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock
Lead Sponsor:
Noha Mansour
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Sepsis is a systemic inflammatory response that has deleterious effects and considered the leading cause of death in critically ill patients 1 . One of the hallmarks of severe sepsis is the progressiv...
Eligibility Criteria
Inclusion
- male or female adult patients, aged 18 years or older with sepsis or septic shock after surgery according to the 2016 third international consensus definitions for sepsis and septic shock
Exclusion
- diagnosis of septic shock longer than 24 hours ago known or suspected disease with a strong indication or contraindication for the study drugs Pregnant and lactating women.
Key Trial Info
Start Date :
April 24 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05402553
Start Date
April 24 2022
End Date
June 1 2023
Last Update
March 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospitals
Tanta, Egypt